Suppr超能文献

新型吡非尼酮肺靶向微球的制备:体外和体内研究

Preparation of novel pirfenidone microspheres for lung-targeted delivery: in vitro and in vivo study.

作者信息

Li Dianbo, Gong Liping

机构信息

Department of Thoracic Surgery, Linyi Tumor Hospital, Linyi, Shandong, People's Republic of China.

出版信息

Drug Des Devel Ther. 2016 Sep 6;10:2815-2821. doi: 10.2147/DDDT.S113670. eCollection 2016.

Abstract

The aim of this study was to develop and characterize pirfenidone (PF)-loaded chitosan microspheres for lung targeting. The microspheres were prepared using the emulsion-solvent evaporation method and characterized by assessing morphology, particle size, and zeta potential. The microspheres had a spherical nature with highly smooth and integrated surfaces. The particle size of microspheres was 4.6±0.3 µm, and the zeta potential was 20.3±1.4 mV. The in vitro release results indicated that the obtained formulation of PF could reach the state of sustained release with a biphasic drug release pattern. It was observed that there was no significant difference in both the percentage of entrapment efficiency and that of drug release before and after the stability study. In vivo, the calculated relative bioavailability indicated greater pulmonary absorption of PF when it was encapsulated in microspheres. According to histopathological studies, no histological change occurred to the rat lung after the administration of PF-loaded chitosan microspheres.

摘要

本研究的目的是开发并表征用于肺部靶向的载有吡非尼酮(PF)的壳聚糖微球。采用乳化溶剂蒸发法制备微球,并通过评估形态、粒径和zeta电位对其进行表征。微球呈球形,表面高度光滑且完整。微球的粒径为4.6±0.3 µm,zeta电位为20.3±1.4 mV。体外释放结果表明,所获得的PF制剂能够达到缓释状态,呈现双相药物释放模式。观察到稳定性研究前后的包封率和药物释放率均无显著差异。在体内,计算得出的相对生物利用度表明,PF包封于微球中时肺部吸收更佳。根据组织病理学研究,给予载有PF的壳聚糖微球后,大鼠肺部未发生组织学变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1dc/5019316/52eaa54510fc/dddt-10-2815Fig1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验